SQUIBB WORLDWIDE DRUG BUSINESS TO BE HEADED BY KENNETH WEG
SQUIBB WORLDWIDE DRUG BUSINESS TO BE HEADED BY KENNETH WEG under a management reorganization announced Sept. 21. Weg, who has been heading the company's international (non-U.S.) pharmaceutical operations, becomes president of Squibb Pharmaceutical Group, one of three newly created operating groups. "The successful marketing of our high-technology, patent-protected pharmaceutical products increasingly requires a coordinated global approach to assure that these products are presented to the health care profession most effectively," Squibb said. "Accordingly, we have organized the worldwide management of these key products in the Squibb Pharmaceutical Group under Ken Weg's leadership." U.S. marketing units falling within the scope of Weg's new responsibilities include E. R. Squibb & Sons and Princeton Pharmaceuticals, with a combined total of almost 1,000 reps. Capoten, Isovue, Azactam and Corgard are among the major product lines. Squibb's worldwide pharmaceutical business approached $ 2 bil. in 1987. William Weathersby, who most recently headed Squibb's U.S. drub business, becomes president of the newly established Squibb Managed Health Care Group. His responsibilities will include the generics unit Squibb Mark, Squibb Novo, diagnostics, OTC products as well as their supporting manufacture and distribution. "The rapidly emerging importance of managed health care organizations and cost containment systems makes it extremely important that these markets be served by a coordinated organization," Squibb President and CEO Jan Leschly explained. "We believed that this approach will assure our ability to serve these markets most effectively in terms of quality, service and cost." Squibb Medical Products Group, a third operating unit consisting of ConvaTec and the Weck Companies, remains unchanged, with Joseph Solari heading the operation as president.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth